Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 6/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3800822 | 0.76 | CYP1A2 (0.48) | CYP1A2ANPEPTP53RECQLHTR2A | |
| SCHEMBL17050195 | 0.76 | ANPEP (0.55) | CYP1A2ANPEPTP53RECQLHTR2A | |
| SCHEMBL6653008 | 0.76 | CYP1A2 (0.48) | CYP1A2ANPEPTP53RECQLHTR2A | |
| SCHEMBL291542 | 0.73 | SIGMAR1 (0.50) | CYP1A2ANPEPHTR2AGAAMAPT | |
| SCHEMBL17031841 | 0.72 | CYP1A2 (0.43) | CYP1A2ANPEPTP53RECQLHTR2A | |
| SCHEMBL17039147 | 0.72 | HTR2A (0.44) | CYP1A2ANPEPTP53RECQLHTR2A | |
| SCHEMBL19368260 | 0.72 | HTR2A (0.44) | CYP1A2ANPEPTP53RECQLHTR2A | |
| SCHEMBL11144393 | 0.71 | CYP1A2 (0.58) | CYP1A2ANPEPHTR2ACYP2A6HRH1 | |
| SCHEMBL23568869 | 0.71 | HTR2A (0.38) | ANPEPHTR2AHRH1HTR2C | |
| SCHEMBL300150 | 0.69 | HTR2A (0.50) | CYP1A2ANPEPTP53RECQLHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4129407-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-3110418-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | CYP1A2 94/4885ANPEP 614/4885TP53 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.